Melanoma Epidemiology

Overview

Journal Hematol Oncol Clin North Am

Specialties Hematology
Oncology

Date 2009 May 26

PMID 19464592

Citations 41

Authors

Margaret A Tucker

Affiliations

Soon will be listed here.

Abstract

Melanoma is a complex, heterogeneous cancer that continues to increase in incidence. Multiple studies have consistently identified major host and environmental risk factors for melanoma. Nevi, particularly dysplastic nevi, confer much higher risks than most pigmentary characteristics. Ultraviolet radiation exposure is the predominant environmental risk factor for melanoma. Recently, both rare high risk susceptibility genes and common polymorphic genes contributing to melanoma risk have been identified.

Citing Articles

A New Approach to Melanoma Treatment: microRNAs.

Ilhan S, Oguz F, Atmaca H Curr Top Med Chem. 2024; 24(16):1362-1376.

PMID: 38676490 DOI: 10.2174/0115680266291290240417081544.

Ferroptosis as a promising therapeutic strategy for melanoma.

Ta N, Jiang X, Zhang Y, Wang H Front Pharmacol. 2023; 14:1252567.

PMID: 37795022 PMC: 10546212. DOI: 10.3389/fphar.2023.1252567.

Different operationalizations of the 2018 WCRF/AICR cancer prevention recommendations and risk of cancer.

Song R, Riseberg E, Petimar J, Wang M, Mucci L, Wu K Br J Cancer. 2023; 129(6):982-992.

PMID: 37500788 PMC: 10491614. DOI: 10.1038/s41416-023-02314-x.

Methoxyflavones from Black Ginger ( Wall. ex Baker) and their Inhibitory Effect on Melanogenesis in B16F10 Mouse Melanoma Cells.

Huo C, Lee S, Yoo M, Lee B, Jang Y, Kim H Plants (Basel). 2023; 12(5).

PMID: 36904043 PMC: 10005586. DOI: 10.3390/plants12051183.

Role of debulking surgery in combination with immune therapy: A successfully treated case of locally advanced mucosal melanoma.

Kimura T, Takahama T, Wakasa T, Adachi S, Akashi Y, Tamura T Mol Clin Oncol. 2021; 16(1):2.

PMID: 34824842 PMC: 8609515. DOI: 10.3892/mco.2021.2435.

References

Gandini S, Sera F, Cattaruzza M, Pasquini P, Picconi O, Boyle P . Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2004; 41(1):45-60. DOI: 10.1016/j.ejca.2004.10.016. View

Celebi J, Ward K, Wanner M, Polsky D, Kopf A . Evaluation of germline CDKN2A, ARF, CDK4, PTEN, and BRAF alterations in atypical mole syndrome. Clin Exp Dermatol. 2005; 30(1):68-70. DOI: 10.1111/j.1365-2230.2004.01656.x. View

Meyskens Jr F, Berwick M . UV or not UV: metals are the answer. Cancer Epidemiol Biomarkers Prev. 2008; 17(2):268-70. DOI: 10.1158/1055-9965.EPI-07-0653. View

Fears T, Bird C, Guerry 4th D, Sagebiel R, Gail M, Elder D . Average midrange ultraviolet radiation flux and time outdoors predict melanoma risk. Cancer Res. 2002; 62(14):3992-6. View

Goldstein A, Chan M, Harland M, Hayward N, Demenais F, Bishop D . Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet. 2006; 44(2):99-106. PMC: 2598064. DOI: 10.1136/jmg.2006.043802. View

Wolff T, Tai E, Miller T . Screening for skin cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2009; 150(3):194-8. DOI: 10.7326/0003-4819-150-3-200902030-00009. View

Tucker M, Halpern A, Holly E, Hartge P, Elder D, Sagebiel R . Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA. 1997; 277(18):1439-44. View

Elder D, Clark Jr W, Elenitsas R, Guerry 4th D, Halpern A . The early and intermediate precursor lesions of tumor progression in the melanocytic system: common acquired nevi and atypical (dysplastic) nevi. Semin Diagn Pathol. 1993; 10(1):18-35. View

Gandini S, Sera F, Cattaruzza M, Pasquini P, Zanetti R, Masini C . Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer. 2005; 41(14):2040-59. DOI: 10.1016/j.ejca.2005.03.034. View

10.

Swerlick R, Chen S . The melanoma epidemic: more apparent than real?. Mayo Clin Proc. 1997; 72(6):559-64. DOI: 10.4065/72.6.559. View

11.

Anderson W, Pfeiffer R, Tucker M, Rosenberg P . Divergent cancer pathways for early-onset and late-onset cutaneous malignant melanoma. Cancer. 2009; 115(18):4176-85. PMC: 2741537. DOI: 10.1002/cncr.24481. View

12.

Bataille V, Grulich A, Sasieni P, Swerdlow A, Newton Bishop J, McCarthy W . The association between naevi and melanoma in populations with different levels of sun exposure: a joint case-control study of melanoma in the UK and Australia. Br J Cancer. 1998; 77(3):505-10. PMC: 2151302. DOI: 10.1038/bjc.1998.81. View

13.

Bishop D, Demenais F, Goldstein A, Bergman W, Bishop J, Bressac-de Paillerets B . Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst. 2002; 94(12):894-903. DOI: 10.1093/jnci/94.12.894. View

14.

. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review. Int J Cancer. 2006; 120(5):1116-22. DOI: 10.1002/ijc.22453. View

15.

Lachiewicz A, Berwick M, Wiggins C, Thomas N . Epidemiologic support for melanoma heterogeneity using the surveillance, epidemiology, and end results program. J Invest Dermatol. 2008; 128(5):1340-2. DOI: 10.1038/jid.2008.18. View

16.

Fargnoli M, Fargnoli M, Pike K, Pfeiffer R, Tsang S, Rozenblum E . MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol. 2008; 128(10):2485-90. PMC: 2835495. DOI: 10.1038/jid.2008.67. View

17.

Gandini S, Sera F, Cattaruzza M, Pasquini P, Abeni D, Boyle P . Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer. 2004; 41(1):28-44. DOI: 10.1016/j.ejca.2004.10.015. View

18.

Raimondi S, Sera F, Gandini S, Iodice S, Caini S, Maisonneuve P . MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int J Cancer. 2008; 122(12):2753-60. DOI: 10.1002/ijc.23396. View

19.

Gallagher R, Spinelli J, Lee T . Tanning beds, sunlamps, and risk of cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev. 2005; 14(3):562-6. DOI: 10.1158/1055-9965.EPI-04-0564. View

20.

Begg C, Orlow I, Hummer A, Armstrong B, Kricker A, Marrett L . Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst. 2005; 97(20):1507-15. DOI: 10.1093/jnci/dji312. View